#1 Clinical Trials Search in Europe

Casimersen

Casimersen, also known as AMONDYS 45 or SRP-4045, is a drug being studied in clinical trials for the treatment of Duchenne Muscular Dystrophy (DMD). This article explores the ongoing research into Casimersen’s safety, effectiveness, and long-term impact on patients with DMD. We’ll look at how it’s being used in clinical settings and what researchers hope to learn about its potential benefits for those living with this challenging condition.

Table of Contents

What is Casimersen?

Casimersen, also known by its brand name AMONDYS 45 or research code SRP-4045, is a medication designed to treat Duchenne Muscular Dystrophy (DMD)[1]. DMD is a genetic disorder characterized by progressive muscle degeneration and weakness, primarily affecting young boys. Casimersen is part of a group of treatments called exon-skipping therapies, which aim to address specific genetic mutations in DMD patients[2].

How Casimersen Works

Casimersen is specifically designed for DMD patients who have a genetic mutation that can be treated by skipping exon 45 in the dystrophin gene[1]. In simple terms, this means the medication helps the body’s cells “skip over” a faulty part of the genetic code. By doing so, it allows the production of a shortened but partially functional dystrophin protein, which is essential for muscle strength and function. This approach aims to slow down the progression of the disease and potentially improve muscle function in patients with this specific type of DMD[1].

Clinical Trials and Research

Casimersen has been the subject of several clinical trials to evaluate its safety and effectiveness. One significant study was an extension trial (NCT03532542) that aimed to assess the long-term effects of Casimersen in patients who had previously participated in other clinical trials[1]. This study involved:

  • Weekly intravenous (IV) infusions of Casimersen at a dose of 30 mg/kg
  • Treatment duration of up to 144 weeks (nearly 3 years)
  • Focus on patients who could benefit from exon 45 skipping

The primary goal of this study was to evaluate the safety and tolerability of long-term Casimersen treatment in DMD patients[1].

How Casimersen is Administered

Casimersen is given as an intravenous (IV) infusion. This means the medication is delivered directly into the bloodstream through a vein. In clinical trials, patients received weekly infusions at a dose of 30 mg/kg of body weight[1]. The treatment is typically administered by healthcare professionals in a clinical setting to ensure proper dosing and to monitor for any immediate reactions.

Safety and Side Effects

The safety of Casimersen was a key focus in clinical trials. Researchers closely monitored for Treatment-emergent Serious Adverse Events (TESAEs)[1]. These are any serious health issues that occur during or after the administration of the drug, whether or not they are directly related to the treatment. TESAEs can include:

  • Life-threatening events
  • Hospitalizations
  • Significant disabilities
  • Other important medical events

It’s important to note that the occurrence of a TESAE doesn’t necessarily mean it was caused by Casimersen, but all such events are carefully documented and analyzed to ensure patient safety[1].

Long-term Observations

To further understand the effects of Casimersen in real-world settings, a long-term observational study (NCT06606340) has been initiated[2]. This study aims to collect data on DMD patients who are receiving Casimersen as part of their routine clinical care. The study will track several important outcomes, including:

  1. Loss of Ambulation (LOA): This measures when a patient loses the ability to walk independently.
  2. Time to Rise from the Floor: This test assesses how quickly a patient can stand up from a lying position.
  3. Time to Walk/Run 10 Meters: This measures the speed at which a patient can move over a short distance.
  4. Upper Limb Function: Using a specialized test called the Performance of Upper Limb Module (PUL 2.0), this assesses arm and hand function.
  5. Pulmonary Function: This measures how well the lungs are working, using a test called Forced Vital Capacity (FVC).
  6. Cardiac Function: This evaluates heart health, particularly looking at how well the heart is pumping blood.

These measurements will help researchers and doctors understand how Casimersen affects various aspects of DMD progression over time in a real-world setting[2].

Aspect Details
Drug Name Casimersen (also known as AMONDYS 45 or SRP-4045)
Condition Treated Duchenne Muscular Dystrophy (DMD)
Mechanism Exon 45 skipping to produce partially functional dystrophin
Administration Weekly intravenous (IV) infusions at 30 mg/kg
Trial Duration Up to 144 weeks with additional 33 days follow-up
Primary Outcomes Safety, tolerability, and treatment-emergent serious adverse events
Secondary Outcomes Muscle function, pulmonary function, cardiac function, and quality of life measures

FAQ

  • What is Casimersen and how does it work? Casimersen is a drug designed to treat Duchenne Muscular Dystrophy (DMD). It works by helping the body 'skip' over a faulty part of a gene, allowing the production of a shortened but partially functional form of a protein called dystrophin, which is essential for muscle function.
  • Who can potentially benefit from Casimersen? Casimersen is specifically designed for DMD patients who have a genetic mutation that is amenable to exon 45 skipping. This means it may help a specific group of DMD patients based on their genetic makeup.
  • How is Casimersen administered in clinical trials? In the clinical trials, Casimersen is given as an intravenous (IV) infusion. Patients receive weekly infusions at a dose of 30 mg/kg of body weight.
  • What are researchers trying to learn about Casimersen in these trials? Researchers are primarily focused on evaluating the safety and tolerability of long-term treatment with Casimersen. They are also studying its effectiveness in improving muscle function and quality of life for DMD patients.
  • How long do the clinical trials for Casimersen last? The extension study mentioned lasts up to 144 weeks (nearly 3 years), with safety monitoring continuing for up to 33 days after the last infusion. There's also a long-term observational study that will collect data on patients using Casimersen in routine clinical practice over an extended period.

Ongoing Clinical Trials on Casimersen

  • Study on the Effects of Casimersen and Golodirsen for Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia Denmark Hungary Ireland +3

Glossary

  • Duchenne Muscular Dystrophy (DMD): A genetic disorder characterized by progressive muscle degeneration and weakness. It's caused by a mutation in the gene that produces dystrophin, a protein essential for maintaining muscle cells.
  • Exon skipping: A therapeutic approach that allows the cellular machinery to 'skip' over faulty sections of genetic code, potentially leading to the production of a shortened but partially functional protein.
  • Intravenous (IV) infusion: A method of delivering medications directly into a vein using a needle or catheter.
  • Treatment-emergent Adverse Event (TEAE): Any unfavorable medical occurrence that happens during a clinical study, whether or not it's considered related to the study drug.
  • Forced Vital Capacity (FVC): A measure of lung function that represents the total amount of air exhaled forcefully after taking a deep breath.
  • Left Ventricular Ejection Fraction (LVEF): A measurement of how much blood the left ventricle pumps out with each contraction, used to evaluate heart function.
  • Loss of Ambulation (LOA): The point at which a person loses the ability to walk independently.
  • Performance of Upper Limb Module (PUL): A test designed to measure upper limb function in patients with DMD.

References

  1. https://clinicaltrials.gov/study/NCT03532542
  2. https://clinicaltrials.gov/study/NCT06606340